"Furthermore, although the reviewed studies have consistently shown the cardioprotective effects of SGLT2 inhibitors against cancer treatment–related cardiotoxicity in tumor-free models, none has yet concurrently demonstrated the cardioprotective and the anticancer effects of SGLT2 inhibitors in tumor-bearing model"
Definitely a space to watch, the SGLT2s are ubiquitous in cardiorenal disease and form part of the fundamental 4 pillars of heart failure treatments along with the ARNIs, beta-blockers and MRAs. They will get great physician buy-in if they can demonstrate cardioprotection in an RCT.
Of course the holy-grail is cardioprotection AND anti-cancer synergy which is yet to be proven in SGLT2s but this could pose a threat to bisantrene if proven.
Gret find @HeyLine
- Forums
- ASX - By Stock
- Cardioprotection thread
"Furthermore, although the reviewed studies have consistently...
-
- There are more pages in this discussion • 350 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M |
Open | High | Low | Value | Volume |
$1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 51 | $1.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.60 | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 54981 | 1.550 |
1 | 700 | 1.520 |
1 | 2750 | 1.510 |
3 | 7984 | 1.505 |
5 | 17550 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.600 | 20000 | 1 |
1.620 | 2000 | 1 |
1.685 | 5000 | 1 |
1.690 | 6570 | 3 |
1.695 | 7731 | 1 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |